No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 484 | 516 | 516 | 685 | 726 | N/A | N/A | N/A |
| Operating profit | $m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | $m | -31 | -63 | -32 | 127 | 26 | N/A | N/A | N/A |
| EPS reported | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | $m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | $m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | $m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | Locked | Locked | Locked |
| Environmental score | Locked | Locked | Locked |
| Social score | Locked | Locked | Locked |
| Governance score | Locked | Locked | Locked |
| Risk rating | Locked | Locked | Locked |
Company overview
Operating globally from its headquarters in Dreieich, Germany, Biotest AG is a pharmaceutical company established in 1946. It specializes in the research, development, manufacturing, and commercialization of biological medicines. The company's operations are structured across its Therapy, Plasma & Services, and Other divisions. Biotest's product portfolio addresses critical needs within hematology, clinical immunology, and intensive care medicine. For instance, Biotest provides treatments for hemophilia, including Haemoctin and Vihuma for hemophilia A, and Haemonine for hemophilia B, addressing both acute episodes and long-term prevention. Its infectious disease portfolio features therapies like Cytotect CP for cytomegalovirus, Varitect for varicella zoster virus, and several Hepatitis B-related products such as Fovepta (for neonate prophylaxis), Hepatect (reinfection prophylaxis), and Zutectra (post-liver transplant reinfection prevention). For immune system disorders and certain neurological conditions, Biotest offers Intratect and IgG Next Generation, targeting primary and secondary antibody deficiencies, and autoimmune diseases. Additionally, Biotest produces Albiomin and Biseko for plasma volume restoration, alongside Cofact and Fibrinogen to address various clotting factor deficiencies, including congenital fibrinogen deficiency. Specialized treatments further comprise Trimodulin for community-acquired pneumonia and COVID-19, and Pentaglobin for bacterial infections. Initially established as Biotest Serum-Institut GmbH, the company adopted its current name, Biotest Aktiengesellschaft, in 1986. As of January 21, 2022, Biotest AG functions as a subsidiary of Grifols, S.A.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Operating globally from its headquarters in Dreieich, Germany, Biotest AG is a pharmaceutical company established in 1946. It specializes in the research, development, manufacturing, and commercialization of biological medicines. The company's operations are structured across its Therapy, Plasma & Services, and Other divisions. Biotest's product portfolio addresses critical needs within hematology, clinical immunology, and intensive care medicine. For instance, Biotest provides treatments for hemophilia, including Haemoctin and Vihuma for hemophilia A, and Haemonine for hemophilia B, addressing both acute episodes and long-term prevention. Its infectious disease portfolio features therapies like Cytotect CP for cytomegalovirus, Varitect for varicella zoster virus, and several Hepatitis B-related products such as Fovepta (for neonate prophylaxis), Hepatect (reinfection prophylaxis), and Zutectra (post-liver transplant reinfection prevention). For immune system disorders and certain neurological conditions, Biotest offers Intratect and IgG Next Generation, targeting primary and secondary antibody deficiencies, and autoimmune diseases. Additionally, Biotest produces Albiomin and Biseko for plasma volume restoration, alongside Cofact and Fibrinogen to address various clotting factor deficiencies, including congenital fibrinogen deficiency. Specialized treatments further comprise Trimodulin for community-acquired pneumonia and COVID-19, and Pentaglobin for bacterial infections. Initially established as Biotest Serum-Institut GmbH, the company adopted its current name, Biotest Aktiengesellschaft, in 1986. As of January 21, 2022, Biotest AG functions as a subsidiary of Grifols, S.A.